Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 201-210 of 532 for center for individualized medicine

Edit search filters
  1. A Study of the Expression and Frequency of Tissue Biomarker Mutations in Breast Cancer that is Resistant or Refractory to Treatment with Trastuzumab and/or Pertuzumab

  2. Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ

  3. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  4. A Study of the Safety and Effectiveness of INC280 Alone and in Combination with Erlotinib, When Compared to Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer Patients with EGFR Mutation and Amplified cMET

    Rochester, MN

  5. A Study Using Targeted Inhibitors to Treat Specific Tumor Mutations in Patients with Meningiomas

    Jacksonville, FL, Rochester, MN

  6. Exercise and Low-Dose Rapamycin in Older Adults with CAD:Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial

    Rochester, MN

  7. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

    Rochester, MN

  8. A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

    Rochester, MN

  9. Erlotinib with or without Bevacizumab in Treating Patients with Stage IV Non-Small Cell Lung Cancer with EGFR Mutations

    Rochester, MN

  10. Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

    Rochester, MN

.

Mayo Clinic Footer